Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3

Oncogene

Volumn 30, Issue 46, 2011, Pages 4678-4686

  Aziz, M H ^a   Shen, H ^a   Maki, C G ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Nutlin; p53; resistance

Indexed keywords

CASPASE 3; CASPASE 7; NUTLIN 3; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; GENE MUTATION; GENOTOXICITY; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CLONE CELLS; HUMANS; IMIDAZOLES; MUTATION; OSTEOSARCOMA; PIPERAZINES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

MURINAE;

EID: 81255185485     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.185     Document Type: Article

References (36)

1. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R et al. (2010). Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221: 49-56.
2. Ashkenazi A. (2008). Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19: 325-331.
3. Blagosklonny MV. (2002). Oncogenic resistance to growth-limiting conditions. Nat Rev Cancer 2: 221-225. (Pubitemid 37328791)
4. Blagosklonny MV. (2005). Carcinogenesis, cancer therapy and chemoprevention. Cell Death Differ 12: 592-602. (Pubitemid 40767162)
5. Brown L, Boswell S, Raj L, Lee SW. (2007). Transcriptional targets of p53 that regulate cellular proliferation. Crit Rev Eukaryot Gene Expr 17: 73-85. (Pubitemid 46511616)
6. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. (2001). Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 19: 1405-1413. (Pubitemid 32202547)
7. De Benedetti VM, Travis LB, Welsh JA, van Leeuwen FE, Stovall M, Clarke EA et al. (1996). p53 mutations in lung cancer following radiation therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev 5: 93-98.
8. Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M et al. (2007). Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res 13: 3380-3387. (Pubitemid 46944926)
9. Efeyan A, Serrano M. (2007). p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6: 1006-1010. (Pubitemid 46708570)
10. Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME et al. (2000). p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19: 3816-3822. (Pubitemid 30621189)
11. Gaitonde SV, Riley JR, Qiao D, Martinez JD. (2000). Conformational phenotype of p53 is linked to nuclear translocation. Oncogene 19: 4042-4049.
12. Haupt Y, Maya R, Kazaz A, Oren M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299. (Pubitemid 27220766)
13. Hollstein M, Sidransky D, Vogelstein B, Harris CC. (1991). p53 mutations in human cancers. Science 253: 49-53. (Pubitemid 21917115)
14. Horn HF, Vousden KH. (2007). Coping with stress: multiple ways to activate p53. Oncogene 26: 1306-1316. (Pubitemid 46328472)
15. Kubbutat MH, Jones SN, Vousden KH. (1997). Regulation of p53 stability by Mdm2. Nature 387: 299-303. (Pubitemid 27220767)
16. Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E et al. (2008). Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 68: 3193-3203.
17. Leonard DG, Travis LB, Addya K, Dores GM, Holowaty EJ, Bergfeldt K et al. (2002). p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer. Clin Cancer Res 8: 973-985. (Pubitemid 34517630)
18. Lovric MM, Hawkins CJ. (2010). TRAIL treatment provokes mutations in surviving cells. Oncogene 29: 5048-5060.
19. Maki CG, Howley PM. (1997). Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 17: 355-363. (Pubitemid 26425625)
20. Maltzman W, Czyzyk L. (1984). UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4: 1689-1694. (Pubitemid 14008276)
21. Mayelzadeh F, Martinez JD. (2007). DNA binding and selective gene induction by different forms of the p53 protein. Oncogene 26: 2955-2963. (Pubitemid 46733644)
22. McDermott U, Longley DB, Galligan L, Allen W, Wilson T, Johnston PG. (2005). Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res 65: 8951-8960. (Pubitemid 41377386)
23. Midgley CA, Lane DP. (1997). p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15: 1179-1189. (Pubitemid 27429621)
24. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P et al. (2003). p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11: 577-590. (Pubitemid 36385115)
25. Milner J, Medcalf EA. (1991). Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65: 765-774. (Pubitemid 121001308)
26. Peng Y, Chen L, Li C, Lu W, Chen J. (2001). Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 276: 40583-40590.
27. Pietenpol JA, Lengauer C, Jordan J, Kinzler KW, Vogelstein B. (1996). Mammalian cells resistant to tumor suppressor genes. Proc Natl Acad Sci 93: 8390-8394. (Pubitemid 26269568)
28. Pinyol M, Hernandez L, Martinez A, Cobo F, Hernandez S, Bea S et al. (2000). INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 156: 1987-1996. (Pubitemid 30641767)
29. Shen H, Moran DM, Maki CG. (2008). Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res 68: 8260-8268.
30. Sherr CJ, Weber JD. (2000). The ARF/p53 pathway. Curr Opin Genet Dev 10: 94-99. (Pubitemid 30113711)
31. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA et al. (2008). The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22: 1337-1344. (Pubitemid 351717524)
32. Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q et al. (2004). Phosphorylation of p53 on key serines is dispensable for transcrip-tional activation and apoptosis. J Biol Chem 279: 53015-53022. (Pubitemid 40051800)
33. Vaseva AV, Marchenko ND, Moll UM. (2009). The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle 8: 1711-1719.
34. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848. (Pubitemid 38174664)
35. Wu GS, Ding Z. (2002). Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 21: 1-8. (Pubitemid 34076373)
36. Wu GS, El-Deiry WS. (1996). Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res 2: 623-633. (Pubitemid 26135334)